Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis

被引:9
作者
Wang, Kai [1 ]
Guan, Chenan [3 ]
Yu, Junhui [1 ]
Jin, Xiaoxiao [1 ]
Sun, Ling [1 ]
Zheng, Lingzhi [1 ]
Xia, Liang [2 ]
Zhang, Yuquan [4 ]
机构
[1] Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Dept Obstet & Gynecol, Linhai 317000, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Dept Neurosurg, Hangzhou 310022, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Dept Kidney Internal Med, Linhai 317000, Zhejiang, Peoples R China
[4] Nantong Univ, Affiliated Hosp, Dept Obstet & Gynecol, Nantong 226001, Jiangsu, Peoples R China
关键词
epithelial ovarian cancer; HER-2/neu; prognosis; meta-analysis; GROWTH-FACTOR RECEPTOR; GENE AMPLIFICATION; PROTEIN EXPRESSION; C-MYC; MOLECULAR MARKERS; PUBLICATION BIAS; ADVANCED-STAGE; OVEREXPRESSION; C-ERBB-2; P53;
D O I
10.18632/oncotarget.20657
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed to conduct a meta-analysis to investigate the association between human epidermal growth factor receptor 2 (HER-2/neu) expression and survival in patients with epithelial ovarian cancer (EOC). HER-2/neu is one of the most frequently studied molecular biological parameters in EOC, but its prognostic impact has not been fully assessed. PubMed and Embase were searched for studies that reported HER-2/neu expression and survival in patients with EOC. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). Hazard ratios (HRs) with 95% confidence interval (CI) were determined using Mantel-Haenszel random-effects model. Publication bias was investigated using funnel plots and Egger's test. A total of 56 studies (N=7212) were included in the analysis. The results showed that patients possessing HER-2/neu expression had significant disadvantages in OS (HR = 1.41; 95% CI, 1.31 to 1.51; P < 0.001) and PFS (HR = 1.38; 95% CI, 1.23-1.56; P < 0.001). The trim-and-fill method, Copas model, and subgroup analyses stratified by the study characteristics confirmed the robustness of the results. The present study findings provided further indication that HER-2/neu expression in patients with EOC has an adverse impact on OS and PFS.
引用
收藏
页码:75528 / 75543
页数:16
相关论文
共 75 条
[1]   Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas [J].
Anglesio, Michael S. ;
Kommoss, Stefan ;
Tolcher, Mary C. ;
Clarke, Blaise ;
Galletta, Laura ;
Porter, Henry ;
Damaraju, Sambasivarao ;
Fereday, Sian ;
Winterhoff, Boris J. ;
Kalloger, Steve E. ;
Senz, Janine ;
Yang, Winnie ;
Steed, Helen ;
Allo, Ghassan ;
Ferguson, Sarah ;
Shaw, Patricia ;
Teoman, Attila ;
Garcia, Joaquin J. ;
Schoolmeester, John K. ;
Bakkum-Gamez, Jamie ;
Tinker, Anna V. ;
Bowtell, David D. ;
Huntsman, David G. ;
Gilks, C. Blake ;
McAlpine, Jessica N. .
JOURNAL OF PATHOLOGY, 2013, 229 (01) :111-120
[2]  
Beckmann R, 1996, DEV BIOL STAND, V86, P326
[3]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[4]  
BERCHUCK A, 1990, CANCER RES, V50, P4087
[5]   HER2 amplification has no prognostic value in sporadic and hereditary ovarian tumours [J].
Brozek I. ;
Kardaś I. ;
Ochman K. ;
Dȩbniak J. ;
Stukan M. ;
Ratajska M. ;
Morzuch L. ;
Emerich J. ;
Limon J. .
Hereditary Cancer in Clinical Practice, 4 (1) :39-42
[6]   Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer [J].
Cai, Yunlang ;
Wang, Jingmei ;
Zhang, Lin ;
Wu, Di ;
Yu, Dandan ;
Tian, Xiaoqiang ;
Liu, Jun ;
Jiang, Xinru ;
Shen, Yang ;
Zhang, Lihua ;
Ren, Mulan ;
Huang, Peilin .
MEDICAL ONCOLOGY, 2015, 32 (01) :1-6
[7]   HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma:: a multicenter study of the GINECO group [J].
Camilleri-Broët, S ;
Hardy-Bessard, AC ;
Le Tourneau, A ;
Paraiso, D ;
Levrel, O ;
Leduc, B ;
Bain, S ;
Orfeuvre, H ;
Audouin, J ;
Pujade-Lauraine, E .
ANNALS OF ONCOLOGY, 2004, 15 (01) :104-112
[8]   Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer [J].
Castellvi, Josep ;
Garcia, Angel ;
Rojo, Federico ;
Ruiz-Marcellan, Carmen ;
Gil, Antonio ;
Baselga, Jose ;
Ramon y Cajal, Santiago .
CANCER, 2006, 107 (08) :1801-1811
[9]   Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer [J].
Chan, JK ;
Loizzi, V ;
Magistris, A ;
Lin, F ;
Rutgers, J ;
Osann, K ;
DiSaia, PJ ;
Berman, ML .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8538-8543
[10]   HER2 Amplification and Clinicopathological Characteristics in a Large Asian Cohort of Rare Mucinous Ovarian Cancer [J].
Chay, Wen-Yee ;
Chew, Sung-Hock ;
Ong, Whee-Sze ;
Busmanis, Inny ;
Li, Xinyun ;
Thung, Sharyl ;
Ngo, Lynette ;
Lim, Sheow-Lei ;
Lim, Yong-Kuei ;
Chia, Yin-Nin ;
Koh, Elisa ;
Pang, Cindy ;
Soh, Lay-Tin ;
Wang, Jin ;
Ho, Tew-Hong ;
Tay, Sun-Kuie ;
Lim-Tan, Soo-Kim ;
Lim, Kiat-Hon ;
Chia, John Whay-Kuang ;
Goh, Liang-Kee .
PLOS ONE, 2013, 8 (04)